Condition: Breast Neoplasms · Neoplasm Metastasis · Sponsor: Eli Lilly and Company
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Alaska Oncology and Hematology | Anchorage, Alaska, United States | Not Yet Recruiting |
| Ironwood Cancer & Research Centers | Chandler, Arizona, United States | Not Yet Recruiting |
| Mayo Clinic in Arizona - Phoenix | Phoenix, Arizona, United States | Not Yet Recruiting |
| The University of Arizona Cancer Center - North Campus | Tucson, Arizona, United States | Not Yet Recruiting |
| Genesis Cancer and Blood Institute | Hot Springs, Arkansas, United States | Not Yet Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Community Cancer Institute | Clovis, California, United States | Not Yet Recruiting |
| City of Hope | Duarte, California, United States | Not Yet Recruiting |
| Epic Care - Emeryville | Emeryville, California, United States | Not Yet Recruiting |
| Marin Cancer Care | Greenbrae, California, United States | Recruiting |
| Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine | Irvine, California, United States | Not Yet Recruiting |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine, California, United States | Not Yet Recruiting |
+ 326 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07174336